AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy NCT07188558Phase 336 sites๐Ÿ“ Gilbert๐Ÿ“ Scottsdale๐Ÿ“ Scottsdale Lyell Immunopharma, Inc. ยท Tests: rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) NCT06299553n/a1 site๐Ÿ“ Milan Incyte Biosciences Italy S.r.l Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL NCT06806033Phase 253 sites๐Ÿ“ Anchorage๐Ÿ“ Clovis๐Ÿ“ Fullerton Hoffmann-La Roche ยท Tests: Obinutuzumab, Glofitamab, Gemcitabine, Oxaliplatin Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma NCT06649812Phase 2114 sites๐Ÿ“ Tucson๐Ÿ“ Tucson๐Ÿ“ Los Angeles National Cancer Institute (NCI) ยท Tests: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma NCT07570017Phase 12 sites๐Ÿ“ Guangzhou๐Ÿ“ Shanghai Guangzhou Lupeng Pharmaceutical Company LTD. ยท Tests: Rocbrutinib, R-GemOx Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL NCT07255963Phase 21 site๐Ÿ“ Suzhou The First Affiliated Hospital of Soochow University ยท Tests: Pirtobrutinib, Lisaftoclax, Rituximab Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma NCT07249905Phase 1, Phase 26 sites๐Ÿ“ Richmond๐Ÿ“ Nedlands๐Ÿ“ Haifa ModeX Therapeutics, An OPKO Health Company ยท Tests: MDX2003 Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma NCT06830031Phase 11 site๐Ÿ“ Tianjin Shanghai Exuma Biotechnology Ltd. ยท Tests: C402-CD19-CAR Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination. NCT07489989Phase 21 site๐Ÿ“ Beijing Daihong Liu ยท Tests: CAR-T Cell Therapy + Chidamide and PD-1 Inhibitor Maintenance Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL NCT05552937Phase 21 site๐Ÿ“ Hangzhou Beijing InnoCare Pharma Tech Co., Ltd. ยท Tests: Tafasitamab and Lenalidomide A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) NCT05139017Phase 2, Phase 3135 sites๐Ÿ“ Glendale๐Ÿ“ Beverly Hills๐Ÿ“ Walnut Creek Merck Sharp & Dohme LLC ยท Tests: Zilovertamab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Bendamustine Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse NCT03356054Phase 1, Phase 21 site๐Ÿ“ Rotterdam Stichting Hemato-Oncologie voor Volwassenen Nederland ยท Tests: R-DHAP, Brentuximab Vedotin Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma NCT05272384Phase 19 sites๐Ÿ“ Birmingham๐Ÿ“ Duarte๐Ÿ“ Sacramento National Cancer Institute (NCI) ยท Tests: Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine, Nivolumab, Positron Emission Tomography Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL NCT04502394Phase 1, Phase 245 sites๐Ÿ“ Goshen๐Ÿ“ Cincinnati๐Ÿ“ Columbus Kartos Therapeutics, Inc. ยท Tests: KRT-232, acalabrutinib Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma NCT04512716EARLY Phase 17 sites๐Ÿ“ Basking Ridge๐Ÿ“ Middletown๐Ÿ“ Montvale Memorial Sloan Kettering Cancer Center ยท Tests: 131-I Apamistamab, CAR T-cell Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma NCT07725406Phase 11 site๐Ÿ“ New York Weill Medical College of Cornell University ยท Tests: Lymphodepleting chemotherapy: Cyclophosphamide, Lymphodepleting chemotherapy: Bendamustine, Lymphodepleting chemotherapโ€ฆ Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas NCT07387848Phase 21 site๐Ÿ“ Beirut American University of Beirut Medical Center ยท Tests: Glofitamab A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL NCT06375733Phase 1, Phase 22 sites๐Ÿ“ Nanning๐Ÿ“ Zhengzhou Genfleet Therapeutics (Shanghai) Inc. ยท Tests: GFH009, Zanubrutinib, GFH009, Zanubrutinib IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL NCT06768905Phase 1, Phase 21 site๐Ÿ“ Dallas University of Texas Southwestern Medical Center ยท Tests: Iomab-B, CAR-T cell Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL NCT06682130Phase 21 site๐Ÿ“ Suzhou The First Affiliated Hospital of Soochow University ยท Tests: Group A๏ผšPatients with PR or ctDNA positivity after salvage treatment, Group B: Patients with CR and ctDNA negative afteโ€ฆ Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors NCT07410494Phase 1, Phase 21 site๐Ÿ“ Beijing Essen Biotech ยท Tests: EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma NCT07189065Phase 241 sites๐Ÿ“ Hefei๐Ÿ“ Beijing๐Ÿ“ Beijing Guangzhou Lupeng Pharmaceutical Company LTD. ยท Tests: Rocbrutinib, Bendamustine, Rituximab, Lenalidomide A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL) NCT06789159Phase 11 site๐Ÿ“ Lexington Pierluigi Porcu ยท Tests: VK-2019 Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma NCT06047197Phase 11 site๐Ÿ“ Tianjin Beijing Yongtai Ruike Biotechnology Company Ltd ยท Tests: RC19D2 cell injection DALY II Japan/MB-CART2019.1 for DLBCL NCT07288879Phase 25 sites๐Ÿ“ Tokyo๐Ÿ“ Tokyo๐Ÿ“ Tokyo Miltenyi Biomedicine GmbH ยท Tests: MB-CART2019.1 Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients NCT04836507Phase 1, Phase 22 sites๐Ÿ“ Seoul๐Ÿ“ Seoul Curocell Inc. ยท Tests: CRC01, Fludarabine, Cyclophosphamide Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) NCT03936153Phase 223 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Beijing Xynomic Pharmaceuticals, Inc. ยท Tests: abexinostat Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure NCT06918912Phase 27 sites๐Ÿ“ Alessandria๐Ÿ“ Bologna๐Ÿ“ Cuneo Istituto Clinico Humanitas ยท Tests: Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate) Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma NCT07062627Phase 21 site๐Ÿ“ Seoul Hyungwoo Cho ยท Tests: Anbal-cel DALY II USA/ MB-CART2019.1 for DLBCL NCT04792489Phase 232 sites๐Ÿ“ Birmingham๐Ÿ“ Gilbert๐Ÿ“ Phoenix Miltenyi Biomedicine GmbH ยท Tests: zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine, Bendamustine
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy